Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study by Willik, K.D. (Kimberly) van der et al.
RESEARCH ARTICLE Open Access
Inflammation markers and cognitive
performance in breast cancer survivors 20
years after completion of chemotherapy: a
cohort study
Kimberly D. van der Willik1,2, Vincent Koppelmans1,2,3, Michael Hauptmann1, Annette Compter4,
M. Arfan Ikram2 and Sanne B. Schagen1,5*
Abstract
Background: Inflammation is an important candidate mechanism underlying cancer and cancer treatment-related
cognitive impairment. We investigated levels of blood cell–based inflammatory markers in breast cancer survivors
on average 20 years after chemotherapy and explored the relation between these markers and global cognitive
performance.
Methods: One hundred sixty-six breast cancer survivors who received post-surgical radiotherapy and six cycles of
adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy on average 20 years before
enrollment were compared with 1344 cancer-free women from a population-based sample (50–80 years old).
Breast cancer survivors were excluded if they used adjuvant hormonal therapy or if they developed relapse,
metastasis, or second primary malignancies. Systemic inflammation status was assessed by the granulocyte-to-
lymphocyte ratio (GLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII).
Cognitive performance was assessed using an extensive neuropsychological test battery from which the
general cognitive factor was derived to evaluate global cognitive performance. We examined the association
between cancer, the general cognitive factor, and inflammatory markers using linear regression models.
Results: Breast cancer survivors had a lower general cognitive factor than non-exposed participants from the
comparator group (mean difference = −0.21; 95% confidence interval (CI) −0.35 to −0.06). Inflammatory markers were
higher in cancer survivors compared with non-exposed participants (mean difference for log(GLR) = 0.31; 95% CI 0.24
to 0.37, log(PLR) = 0.14; 95% CI 0.09 to 0.19, log(SII) = 0.31; 95% CI 0.24 to 0.39). The association between higher levels
of inflammatory markers and lower general cognitive factor was statistically significant in cancer survivors but not
among non-exposed participants. We found a group-by-inflammatory marker interaction; cancer survivors showed
additional lower general cognitive factor per standard deviation increase in inflammatory markers (P for interaction for
GLR = 0.038, PLR = 0.003, and SII = 0.033).
Conclusions: This is the first study to show that (1) cancer survivors have increased levels of inflammation on average
20 years after treatment and (2) these inflammatory levels are associated with lower cognitive performance. Although
this association needs verification by a prospective study to determine causality, our findings can stimulate research on
the role of inflammation in long-term cognitive problems and possibilities to diminish such problems.
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Background
Patients with cancer frequently report cognitive prob-
lems that can affect their quality of life and daily func-
tioning substantially. Studies have shown that patients
with non-central nervous system (non-CNS) cancer can
experience cognitive problems during and after comple-
tion of treatment including chemotherapy, and a sub-
group of patients had cognitive problems up to 20 years
after treatment [1, 2].
The cancer survivor population is aging and growing
because of increased life expectancy and more specific-
ally because of advances in cancer treatment and im-
proved screening. In turn, this results in an increasing
number of cancer survivors coping with cognitive prob-
lems. The driving forces underlying these cognitive
problems have not been sufficiently clarified, impeding
the approach and process of developing effective inter-
ventions. Cognitive problems in patients with cancer
could be induced by cancer itself, cancer-related treat-
ment, or shared risk factors for the development of both
cancer and cognitive problems [3, 4]. Disentangling the
effects and mechanisms of these causes of disruption of
normal cognitive performance is challenging. Different
mechanisms, including genetic susceptibility, telomere
shortening, changes in hormone levels, and inflamma-
tion, have been proposed and revealed [3].
In recent years, inflammation in particular has been
suggested as an important and potentially intervenable
mechanism in the pathogenesis of cognitive problems in
patients with cancer. Higher levels of inflammatory fac-
tors such as cytokines are observed in patients with can-
cer prior to start of any treatment [5], during
chemotherapy [6–10], and after chemotherapy [11, 12]
up to 5 years after treatment initiation [13]. Several stud-
ies found an association between cytokines and cognitive
impairment in patients with cancer across different cog-
nitive domains, such as psychomotor speed [8], execu-
tive functioning [14], and memory [5, 10, 11, 13].
However, these studies did not agree on the involved cy-
tokines or on the affected cognitive domain. Moreover,
because the longest follow-up in these studies was 5
years, it remains unknown whether inflammation also
has a role in longer-term or late cognitive problems. Fill-
ing this knowledge gap is important as insight into
underlying causes of (long-term) cognitive impairment
helps to identify those cancer patients at increased risk
of developing cognitive problems and opens venues for
preventive and therapeutic interventions.
Most studies examined the inflammation status by
investigating cytokines using different cytokine panels
[5, 6, 8–19]. In contemporary studies, systemic
inflammatory response markers measured in blood,
including the neutrophil-to-lymphocyte ratio (NLR),
platelet-to-lymphocyte ratio (PLR), and systemic
immune-inflammation index (SII), are increasingly
used. These markers have reliable prognostic and pre-
dictive value in patients with cancer and can easily be
calculated from readily available standard full blood
examination, making them more convenient to use in
a clinical setting [20–24]. If related to cognitive prob-
lems, these markers could potentially be used as bio-
markers for cancer-related cognitive impairment.
In this study, we investigated global cognitive perform-
ance, levels of blood cell–based inflammatory markers,
and their relation in breast cancer survivors who had
received post-surgical radiotherapy and six cycles of ad-
juvant cyclophosphamide, methotrexate, and fluorouracil
(CMF) chemotherapy on average more than 20 years
previously. We furthermore examined whether inflam-
mation and cognitive performance were differentially
associated between breast cancer survivors and
cancer-free women from a population-based sample.
Methods
Study population
In this study, we selected women who had survived
breast cancer and had received adjuvant CMF chemo-
therapy. We compared them with women from the gen-
eral population, who were cancer-free and had never
received chemotherapy.
Breast cancer survivors
Women with a history of unilateral, invasive breast can-
cer were identified on the basis of registries of the
Netherlands Cancer Institute in Amsterdam and the
Daniel den Hoed Cancer Clinic of the Erasmus Medical
Center in Rotterdam as described previously [2]. Briefly,
women were selected if they had received post-surgical
radiotherapy and six cycles of adjuvant CMF chemother-
apy between 1976 and 1995.
Breast cancer survivors were eligible if they were 50–
80 years old at the time of inclusion in 2008, if invasive
breast cancer was their first and only malignancy, if they
had not developed relapse or distant metastasis, if they
had sufficient command of the Dutch language, and if
they did not have any contraindications for magnetic
resonance imaging (MRI). In addition, ever use of hor-
monal therapy was applied as an exclusion criterion.
Because adjuvant hormonal therapy was not part of the
standard treatment for patients with breast cancer in the
Netherlands until the mid-1990s, only a few women re-
ceived this treatment. To enhance homogeneity within
the group of breast cancer survivors, we included hor-
mone treatment-naïve cancer survivors only.
Three hundred fifty-nine breast cancer survivors were
assessed for eligibility and 292 were selected. Of these
292 women, 196 agreed to participate and provided
informed consent. We previously reported on cognitive
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performance of these survivors in comparison with
cancer-free women identified within the Rotterdam
Study [2]. For the present study, the following additional
inclusion criteria were defined: availability of blood mea-
surements and completeness of neuropsychological test
data to calculate the general cognitive factor. Thirty of
the 196 (15.3%) breast cancer survivors were excluded
because of missing data on blood measurements (n = 5)
and incomplete data of neuropsychological tests (n = 25,
Fig. 1a). Because breast cancer survivors did not receive
an extensive dementia screening, history of dementia
was not applied as an exclusion criterion. However,
based on the interviews with a trained psychologist, sub-
jective memory complaints, cognitive tests, and brain
MRI, it is unlikely that the included breast cancer survi-
vors had dementia at the time of examinations.
Population-based non-exposed participants
Cancer-free women were selected from the Rotterdam
Study, an ongoing population-based prospective cohort
that started in 1990 in Rotterdam, the Netherlands. The
main objective of the Rotterdam Study is to investigate
risk factors of diseases in the elderly. By the end of 2008,
the Rotterdam Study consisted of three subcohorts,
comprising 14,926 individuals. The design of the Rotter-
dam Study was described in detail previously [25].
The third subcohort (RS-III) started in 2006 and was
the first cohort in which an extensive set of neuro-
psychological tests was implemented at baseline. For this
reason, RS-III was chosen as the reference subcohort,
which was composed of 3392 participants (65% out of
invitees). From these participants, women 50–80 years
old without a history of cancer or dementia were eligible
as non-exposed participants (n = 1574). This sample
comprised the non-exposed participants used in our
previous cognitive study [2]. Two hundred thirty persons
were additionally excluded because of lack of blood
measurements (n = 39) and incomplete data of
neuropsychological tests (n = 191), resulting in 1344
non-exposed participants (Fig. 1b).
Assessment of inflammatory markers
All participants had fasting blood samples taken during
the research center visit. Full blood count measurements
were performed by using a COULTER® Ac·T diff2™
Hematology Analyzer (Beckman Coulter, San Diego, CA,
USA) directly after the blood sample was drawn.
Hematologic measurements included absolute granulo-
cyte, lymphocyte, and platelet counts in 109 per liter.
We used the granulocyte count as proxy for the neu-
trophil count because we did not have this measurement
available in our sample. Because most of the granulo-
cytes are represented by neutrophils, we believe this did
not affect our results [26, 27]. For accuracy purposes, we
will refer to the granulocyte-to-lymphocyte ratio (GLR)
instead of using the term NLR.
The GLR and PLR were calculated as the ratio of gran-
ulocyte count to lymphocyte count and as the ratio of
platelet count to lymphocyte count, respectively [28].
The SII was defined as platelet count times the GLR
[22]. Because they are either ratios or indices, the de-
rived inflammatory markers did not have a unit.
Assessment of cognitive performance
Cognitive performance was evaluated between November
2009 and June 2010 for breast cancer survivors and between
February 2006 and December 2008 for non-exposed partici-
pants on the same day the blood sample was drawn. Cogni-
tive performance was assessed by a neuropsychological
battery in the research center of the Rotterdam Study. Six
tests were administered: the Mini–Mental State Examin-
ation, Letter-Digit Substitution Test (LDST), Word Fluency
Test (WFT), Stroop Test (reading, naming, and interfer-
ence), Purdue Pegboard Test (PPB) (right, left, and both
hands), and 15-Word Learning Test (15-WLT) (immediate
recall, delayed recall, and recognition). Global cognitive
Fig. 1 a Flowchart for breast cancer survivors. b Flowchart for non-exposed participants. Abbreviation: MRI magnetic resonance imaging
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performance was assessed via the general cognitive factor,
which was generated by using principal component analysis
of the following tests: LDST (total completion time), WFT
(number of words), Stroop interference (time in seconds,
adjusted for errors), PPB test (total number of pins across
three subtasks), and 15-WLT (number of words during de-
layed recall) [29].
Other assessments
We assessed education level (primary: primary education;
lower: lower general education, intermediate general edu-
cation, or lower vocational education; intermediate: inter-
mediate vocational education or higher general education;
higher: higher vocational education or university) and
smoking status (current, former, or never) by interview.
Body mass index (BMI) (in kilograms per square meter)
was computed from measurements of height and weight.
Diabetes mellitus was defined as use of antidiabetic medi-
cation, a fasting serum glucose level of at least 7.1 mmol/
L, or a random serum glucose level of at least 11.1 mmol/
L [30]. History of stroke or myocardial infarction was
assessed by interview [31, 32]. Symptoms of depression
were evaluated with the Center for Epidemiologic Studies
Depression scale (CES-D), which was converted to a
sum-score [33]. We had no information about anxiety and
fatigue and therefore could not control for these
symptoms.
Statistical analyses
Linear regression models were used to investigate mean
differences in the general cognitive factor and inflamma-
tory markers between breast cancer survivors and
non-exposed participants. Inflammatory markers were
log-transformed because of their skewed distribution.
We constructed two nested models: model I was ad-
justed for age (continuous) and education (four categor-
ies), and model II was additionally adjusted for smoking
status (three categories), BMI (continuous), diabetes
mellitus (yes/no), history of stroke (yes/no), history of
myocardial infarction (yes/no), and CES-D sum-score
(continuous). To investigate whether levels of the gen-
eral cognitive factor were explained by different inflam-
matory markers, we adjusted additionally for each
inflammatory marker separately.
The association between the general cognitive factor
and inflammatory markers was investigated for breast
cancer survivors and non-exposed participants using lin-
ear regression models. To study whether this association
was stronger in breast cancer survivors than in
non-exposed participants, we computed interaction
terms between history of cancer/cancer treatment and
each inflammatory marker. We explored effect modifica-
tion by stratifying for mean BMI.
Since mean age was higher in the breast cancer survivors
compared with the non-exposed participants (Table 1), we
repeated all analyses using age-matched non-exposed par-
ticipants to minimize residual confounding. These analyses
provided estimates comparable to the analyses using all
non-exposed participants and therefore are not reported
separately.
Multiple imputation was used for missing data on co-
variates (generally between 0.07% and 0.3% with a max-
imum of 1.8% for the CES-D sum-score) with five
imputed datasets, based on history of cancer/cancer
treatment, inflammatory markers, general cognitive fac-
tor, and other covariates (that is, age, sex, education,
BMI, smoking status, presence of diabetes mellitus, his-
tory of stroke, history of myocardial infarction, and
CES-D sum-score). Rubin’s method was used for pooled
regression coefficients (β) and 95% confidence intervals
(CIs) [34]. All analyses were performed by using IBM
SPSS Statistics Version 24.0 and RStudio Version 3.3.2.
All statistical tests were two-sided, and a P value of less
than 0.05 was considered statistically significant.
Results
Characteristics of breast cancer survivors and non-exposed
participants are presented in Table 1. Breast cancer survi-
vors were older than non-exposed participants. Addition-
ally, they generally had completed higher levels of
education and more often had diabetes mellitus and a his-
tory of myocardial infarction. Lastly, although the numbers
of never smokers were similar between the two groups,
breast cancer survivors were more frequently former
smokers and less often current smokers.
Inflammatory markers
Breast cancer survivors had higher median levels of
GLR, PLR, and SII than non-exposed participants. His-
tory of breast cancer/cancer treatment was associated
with higher inflammatory markers, also after adjustment
for age, education, smoking, BMI, diabetes mellitus, his-
tory of stroke, history of myocardial infarction, and
CES-D sum-score (mean difference for log(GLR) = 0.31,
95% CI 0.24 to 0.37, log(PLR) = 0.14, 95% CI 0.09 to
0.19, log(SII) = 0.31, 95% CI 0.24 to 0.39; Table 2). In-
flammatory markers were positively associated with age
in both groups [35].
Cognitive performance
Breast cancer survivors had a lower general cognitive
factor than non-exposed participants (mean difference =
−0.21, 95% CI −0.35 to −0.06, corresponding with an ef-
fect of 3.6 years of age given a decline in general cogni-
tive factor of 0.59 points per 10 years; Table 2) [29].
Further adjustment for inflammatory factors changed
the estimates slightly, indicating that inflammatory
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markers explained only a small part of the difference in
general cognitive factor in addition to the effect of
history of cancer/cancer treatment (mean difference for
history of cancer/cancer treatment after adjustment for
log(GLR) = −0.18; 95% CI −0.33 to 0.02, log(PLR) =
−0.21; 95% CI −0.36 to 0.06, log(SII) = −0.19; 95% CI
−0.34 to 0.03).
Association between cognitive performance and
inflammatory markers by cancer status
A lower general cognitive factor was associated with
higher inflammatory markers in breast cancer survivors
(Table 3). In non-exposed participants, higher inflamma-
tory markers tended to be associated with a lower general
cognitive factor, albeit not statistically significant.
Table 2 Association between the general cognitive factor and history of cancer and inflammatory markers and history of cancer
Outcome Model I Model II
Mean difference (95% CI) Mean difference (95% CI)
Inflammatory marker*
Log GLR 0.30 (0.24 to 0.36) 0.31 (0.24 to 0.37)
Log PLR 0.16 (0.10 to 0.21) 0.14 (0.09 to 0.19)
Log SII 0.30 (0.23 to 0.38) 0.31 (0.24 to 0.39)
Cognition†
General cognitive factor −0.18 (−0.34 to −0.03) −0.21 (−0.35 to −0.06)
Abbreviations: CI confidence interval, GLR granulocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SII systemic immune-inflammation index
Model I is a linear regression of the general cognitive factor or log-transformed inflammatory markers on cancer status adjusted for age and education. Model II is
as model I plus adjustment for smoking status, body mass index, diabetes mellitus, history of stroke, history of myocardial infarction, and Center for Epidemiologic
Studies Depression Scale (CES-D) sum-score
*Mean difference in general cognitive factor between breast cancer survivors and non-exposed participants
†Mean difference in inflammatory markers between breast cancer survivors and non-exposed participants
Table 1 Demographics and characteristics of breast cancer survivors and non-exposed participants
Characteristic Breast cancer survivors
(n = 166)
Non-exposed participants
(n = 1344)
P
Age in years, mean (SD) 64.0 (6.7) 57.9 (5.2) <0.001
Education level, no. (%) <0.001
Primary 14 (8.4) 158 (11.8)
Low 59 (35.5) 616 (45.8)
Intermediate 33 (19.9) 287 (21.4)
High 60 (36.1) 283 (21.1)
Body mass index in kg/m2, mean (SD) 26.9 (4.6) 27.4 (4.8) 0.181
Smoking status, no. (%) <0.001
Current 16 (9.6) 295 (21.9)
Former 93 (56.0) 574 (42.7)
Diabetes mellitus, no. (%) 14 (8.4) 54 (4.0) 0.008
History of stroke, no. (%) 1 (0.6) 19 (1.4) 0.715
History of myocardial infarction, no. (%) 6 (3.6) 11 (0.8) 0.001
CES-D sum-score, mean (SD) 14.5 (3.6) 14.8 (4.4) 0.450
General cognitive factor, mean (SD) −0.39 (1.14) 0.05 (0.97) <0.001
Inflammatory markers, median (IQR)
GLR 2.06 (1.67–2.66) 1.52 (1.20–1.92) <0.001
PLR 145 (119–176) 124 (102–151) <0.001
SII 618 (469–796) 443 (328–595) <0.001
Age at breast cancer diagnosis in years, mean (SD) 42.9 (5.6)
Time since breast cancer diagnosis, mean (SD) 21.0 (4.5)
Abbreviations: CES-D Center for Epidemiologic Studies Depression Scale, GLR granulocyte-to-lymphocyte ratio, IQR interquartile range, PLR platelet-to-lymphocyte
ratio, SD standard deviation, SII systemic immune-inflammation index
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The interaction term between inflammatory markers
and history of cancer/cancer treatment was significant
for each inflammatory marker, indicating that the
association between higher inflammation levels and lower
general cognitive factor was more pronounced in breast
cancer survivors than in non-exposed participants
(P for interaction between cancer and standardized
log-transformed GLR = 0.038, PLR = 0.003, and SII =
0.033; Fig. 2).
The association between higher inflammatory markers
and lower general cognitive factor differed more between
breast cancer survivors and non-exposed participants
with a higher BMI than in those with a lower BMI.
However, stratified analyses for BMI showed that the ef-
fect of one–standard deviation increase in inflammatory
marker on general cognitive factor was higher among
breast cancer survivors with a BMI below 27.3 kg/m2
compared with those with a higher BMI (Table 4).
Discussion
This study is the first report investigating the associ-
ation between blood cell–based inflammatory markers
and cognitive performance in breast cancer survivors
with an average time since cessation of chemotherapy
of more than 20 years. Breast cancer survivors had
lower global cognitive performance and higher inflam-
matory markers compared with women without a his-
tory of cancer. The tendency for lower global
cognitive performance with higher inflammatory
markers was more pronounced in breast cancer survi-
vors, suggesting a potential role for inflammation in
the pathophysiology of cognitive problems in cancer
Table 3 Association between the general cognitive factor and inflammatory markers in breast cancer survivors and in non-exposed
participants
Inflammatory
marker per SD
increase
Breast cancer survivors Non-exposed participants P for
interaction†Mean difference* (95% CI) Mean difference* (95% CI)
Model I
Log GLR −0.24 (−0.40 to −0.08) −0.04 (−0.09 to 0.00) 0.061
Log PLR −0.13 (−0.29 to 0.03) 0.05 (0.01 to 0.10) 0.003
Log SII −0.22 (−0.38 to −0.07) −0.03 (−0.08 to 0.01) 0.053
Model II
Log GLR −0.23 (−0.39 to −0.08) −0.02 (−0.07 to 0.02) 0.038
Log PLR −0.18 (−0.33 to −0.02) 0.03 (−0.01 to 0.08) 0.003
Log SII −0.23 (−0.38 to −0.07) −0.01 (−0.06 to 0.03) 0.033
Abbreviations: CI confidence interval, GLR granulocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SD standard deviation, SII systemic
immune-inflammation index
Model I is a linear regression of the general cognitive factor on each log-transformed inflammatory marker adjusted for age and education. Model II is as model I
plus adjustment for smoking status, body mass index, diabetes mellitus, history of stroke, history of myocardial infarction, and Center for Epidemiologic Studies
Depression Scale (CES-D) sum-score
*Mean difference in general cognitive factor per standard deviation increase in inflammatory marker
†P value for interaction term between history of cancer/cancer treatment and inflammatory marker
Fig. 2 a Interaction of log(GLR) and cancer status with the general cognitive factor as outcome. b Same as a, for log (PLR). c Same as a and b, for
log(SII). Model used for figure is adjusted for age only. Abbreviations: GLR granulocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SII
systemic immune-inflammation index
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survivors. This effect was not modified by BMI. More
insight in mechanisms underlying cognitive problems
could help identifying those women who are at an in-
creased risk of cognitive problems and developing
prevention strategies.
We previously reported on differences in cognitive
performance between breast cancer survivors and
non-exposed participants [2]. In this previous study, we
tested between-group performance differences of indi-
vidual cognitive outcome measures that were currently
used to construct the general cognitive factor and ob-
served that breast cancer survivors performed worse
compared with non-exposed participants within several
cognitive domains. This suggested that cognitive prob-
lems in cancer survivors can be long-lasting. In the
present study, we evaluated global cognitive perform-
ance using the general cognitive factor because we did
not expect a specific cognitive domain to be affected by
inflammation. We chose to use a robust cognitive sum-
mary measure, thereby reducing the number of
comparisons.
Interestingly, levels of inflammatory markers were
higher in breast cancer survivors, compared with
non-exposed participants, on average 20 years after can-
cer treatment. Inflammation plays a critical role in
tumorigenesis, tumor progression, and cancer metastasis
[36, 37]. Research has shown that chronic inflammation
is associated with an increased cancer risk [37]. More-
over, different markers of inflammation, such as cyto-
kines, C-reactive protein, and NLR, are often elevated in
patients with cancer and are associated with poor
survival [9, 15–17, 24, 38]. One study investigating
inflammation levels after cancer treatment found that
C-reactive protein and cytokine levels were elevated up
to 5 years after treatment [19]. Our observation that sys-
temic inflammation markers are higher in breast cancer
survivors compared with non-exposed participants on
average 20 years after cancer treatment suggests deregu-
lation of the immune system. Whether this is a conse-
quence of cancer or cancer treatment (or both) or a
pre-existing deregulation before cancer development
cannot be determined with the present study.
The found association of blood cell–based inflamma-
tory markers and cognitive performance in breast cancer
survivors is in line with previous observations before,
during, and shortly after therapy [6, 17, 18]. Two studies
investigated the link between inflammation and cogni-
tive performance prior to the start of cancer treatment.
The first study showed that elevated levels of
interleukin-6 (IL-6) in patients with acute myelogenous
leukemia or myelodysplastic syndrome were associated
with poorer executive functioning before cancer treat-
ment [14]. The second study showed that high levels of
soluble tumor necrosis factor receptor type II
(sTNF-RII) were related to reduced verbal memory per-
formance in patients with newly diagnosed breast cancer
[5]. More studies in patients with breast cancer have
tried to elucidate the role of inflammation in impaired
cognitive performance during chemotherapy and two of
these studies identified specific cytokines to be involved.
Williams et al. focused on sTNR-RII and found that
higher levels of this receptor were associated with visual
memory performance [10]. Cheung et al. observed an
association between increased levels of IL-6 and IL-1β
Table 4 Association between the general cognitive factor and inflammatory markers in breast cancer survivors and in non-exposed
participants stratified for mean body mass index
Inflammatory
marker per
SD increase
Breast cancer survivors Non-exposed participants P for
interaction†Mean difference* 95% CI Mean difference* 95% CI
BMI < 27.3 kg/m2
n = 104 n = 749
Log GLR −0.29 −0.49 to −0.10 −0.04 −0.10 to 0.02 0.480
Log PLR −0.22 −0.42 to −0.02 0.01 −0.05 to 0.08 0.309
Log SII −0.28 −0.48 to −0.09 −0.04 −0.10 to 0.02 0.564
BMI > 27.3 kg/m2
n = 62 n = 595
Log GLR −0.16 −0.41 to 0.09 0.01 −0.06 to 0.08 0.013
Log PLR −0.16 −0.42 to 0.10 0.05 −0.02 to 0.12 <0.001
Log SII −0.12 −0.38 to 0.14 0.02 −0.05 to 0.09 0.005
Abbreviations: BMI body mass index, CI confidence interval, GLR granulocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SD standard deviation, SII
systemic immune-inflammation index
Model I is a linear regression of the general cognitive factor on each log-transformed inflammatory marker adjusted for age and education. Model II is as model I
plus adjustment for smoking status, diabetes mellitus, history of stroke, history of myocardial infarction, and Center for Epidemiologic Studies Depression Scale
(CES-D) sum-score.
*Mean difference in general cognitive factor per standard deviation increase in inflammatory marker
†P value for interaction term between history of cancer/cancer treatment and inflammatory marker
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and poorer psychomotor speed performance during
chemotherapy [8]. Shortly after cancer treatment, higher
levels of sTNF-RII were associated with increased mem-
ory complaints [11], and on average 5 years after cancer
treatment, elevated IL-6 and TNFα levels were associ-
ated with worse verbal memory [13]. Importantly, the
association between inflammation and cognitive per-
formance is supported by animal studies. Acute peripheral
immune challenges using lipopolysaccharide resulted in
cognitive impairments in a spatial working memory task
in mice. Cognitive impairments were observed 1.5–2 h
after injection in tumor-bearing mice but not in
tumor-free mice. These cognitive effects could be pre-
vented when using a technique to enhance innate immune
reactivity [39]. Together, these results support the hypoth-
esis that inflammation has a role in the complex patho-
genesis of both short-term and longer-term cognitive
problems in patients with cancer.
Owing to our study design, we cannot determine
whether the association between inflammation and im-
paired cognitive performance is causal. However, also a
causal association could not illuminate the exact under-
lying mechanisms by which inflammation leads to brain
changes and subsequent cognitive problems. Peripheral
pro-inflammatory cytokines are able to cross the blood–
brain barrier, which may initiate the release of local cyto-
kines [40]. Local cytokine production could result in
neurotransmitter deregulation, increased oxidative stress,
and decreased neurogenesis and neuroplasticity, which in
turn can lead to cognitive dysfunction [41]. It is also
possible that inflammation induces epigenetic changes
and chromosomal instability, which can be persistent and
therefore could be associated with long-term cognitive
problems [42].
Our study has several strengths. First, we have a large
sample size of breast cancer survivors who have been
treated on average more than 20 years ago, enabling us
to investigate long-term effects. Moreover, we used
non-exposed participants from a population-based cohort
study, who underwent the same examinations as the
breast cancer survivors. This design provided standardized
ascertainments of outcome and covariates. All participants
received a neuropsychological test battery, enabling us to
investigate global cognitive function by the general cogni-
tive factor. Lastly, we were able to investigate inflamma-
tion status using blood cell–based inflammatory markers,
which are low-cost and easy to use in the clinic.
Study limitations include the design by which we cannot
disentangle the effects of cancer and cancer treatment on
cognition and levels of inflammatory markers. Some studies
show that patients treated with chemotherapy have higher
inflammatory markers during and after treatment compared
with chemotherapy-naïve patients [12]. However, because
inflammatory markers and cognitive problems can already
occur in patients with newly diagnosed cancer, it is unlikely
that inflammation is important only in chemotherapy-
treated patients [5]. Owing to the cross-sectional design, we
do not have information about cognitive performance and
levels of inflammatory markers before cancer diagnosis and
treatment. Moreover, patients with breast cancer nowadays
receive chemotherapy regimens other than CMF, either with
or without adjuvant endocrine therapy, limiting the
generalizability to current patients with breast cancer.
However, cyclophosphamide and 5-fluoroacil are still
frequently used in other regimens for adjuvant chemo-
therapy. Furthermore, we were not able to exclude indi-
viduals whose systemic inflammatory markers may have
been elevated because of acute infections and to control
for acute-phase reactants such as C-reactive protein,
but we expect that this effect is similar for cancer survi-
vors and non-exposed participants. Lastly, we need to
emphasize that by measuring the GLR, PLR, and SII, we
cannot identify the exact phenotype of the underlying
immune cell populations. Although these markers are
proven to be related to chronic systemic inflammation,
it is unknown whether they also reflect higher levels of
pro-inflammatory cytokines. In other words, we cannot
confirm that observed shifts in the granulocytes, lym-
phocytes, and platelets cause higher cytokine levels and
thereby are functional. To elucidate the exact immune
cell populations involved in increases of the GLR, PLR,
and SII, determination of different cytokines is needed.
Conclusions
We found that breast cancer survivors who had been
treated with chemotherapy on average more than 20 years
ago have higher blood cell–based inflammatory markers
compared with women without a history of cancer. Higher
levels of inflammatory markers tended to be associated
with poorer cognitive performance in both cancer survi-
vors and cancer-free women, and expression was stronger
in breast cancer survivors. This finding suggests that
inflammation could have a role in the pathogenesis of
long-term cognitive impairment in cancer survivors.
Further prospective studies are important to determine
the causality of the association and to investigate the
effects of lowering inflammation on the development of
cognitive problems in cancer patients and survivors, for
instance, by exercise or anti-inflammatory drugs.
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